Looks like you’re on the UK site. Choose another location to see content specific to your location
Pfizer achieves top-line result for pneumonia treatment
Pfizer has announced it has achieved its top-line results in a landmark study of its Prevenar 13 pneumonia vaccine.
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) has involved around 85,000 patients, all of which were 65 years of age or older, making it the largest double-blind, randomised, placebo-controlled efficacy research ever conducted in adults.
According to the company, the primary objective was to demonstrate the efficacy of the treatment against a first episode of vaccine-type community-acquired pneumonia (CAP).
In addition, the CAPiTA study also met the secondary targets, which were relating to its use against non-bactermic, non-invasive CAP and a first episode of vaccine-type invasive pneumococcal disease.
Dr William Gruber, Pfizer's senior vice-president for vaccine clinical research, said: "We are pleased with the outcome of the CAPiTA study, which demonstrated that Prevenar 13 can prevent vaccine-type pneumococcal community-acquired pneumonia in adults."
The results of the trial are likely to form a key consideration as the company seeks to gain new or updated recommendations for the treatment.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard